Affordable Access

Access to the full text

Effect of omega-3 fatty acids supplementation on cardio-metabolic and oxidative stress parameters in patients with chronic kidney disease: a systematic review and meta-analysis

  • Fazelian, Siavash1
  • Moradi, Fatemeh2
  • Agah, Shahram3
  • Hoseini, Akramsadat3
  • Heydari, Hafez4
  • Morvaridzadeh, Mojgan5
  • Omidi, Amirhosein5
  • Pizarro, Ana Beatriz6
  • Ghafouri, Atie3
  • Heshmati, Javad5
  • 1 Shahrekord University of Medical Sciences, Shahrekord, Iran , Shahrekord (Iran)
  • 2 School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran , Isfahan (Iran)
  • 3 Iran University of Medical Sciences, Tehran, Iran , Tehran (Iran)
  • 4 Sabzevar University of Medical Sciences, Sabzevar, Iran , Sabzevar (Iran)
  • 5 Farabi Hospital, Faculty of Nutrition Sciences and Food Technology, Postal Code: 6715847141, Isar Square, Kermanshah, Iran , Kermanshah (Iran)
  • 6 Pontificia Universidad Javeriana, Bogotá, Colombia , Bogotá (Colombia)
Published Article
BMC Nephrology
Springer (Biomed Central Ltd.)
Publication Date
May 01, 2021
DOI: 10.1186/s12882-021-02351-9
Springer Nature


BackgroundOmega-3 fatty acids (FAs) have been suggested as a beneficial supplement in chronic kidney disease (CKD) patients, but the results of randomized clinical trials (RCTs) are controversial. We conducted a systematic review and meta-analysis to evaluate all the RCTs about the impact of omega-3 FAs supplementation on cardiometabolic outcomes and oxidative stress parameters in patients with CKD.MethodsWe performed a systematic database search in PubMed/MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane Central, up to May 2020. We included all placebo-controlled randomized trials that assessed the effect of omega-3 FAs supplementation on any cardiometabolic outcomes: blood pressure, total cholesterol (TC), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) or triglycerides (TG) and oxidative stress parameters. Data were pooled using DerSimonian–Laird’s random-effects model.ResultsFinally, thirteen articles met the inclusion criteria for this review omega-3 FAs supplementation significantly decrease TC (SMD: -0.26; 95% CI: − 0.51, − 0.02; I2 = 52.7%), TG (SMD: -0.22; 95% CI: − 0.43, − 0.02; I2 = 36.0%) and Malondialdehyde (MDA) levels (SMD: -0.91; 95% CI: − 1.29, − 0.54; I2 = 00.0%) and also significantly increase superoxide dismutase (SOD) (SMD: 0.58; 95% CI: 0.27, 0.90; I2 = 00.0%) and Glutathione peroxidase (GPx) (SMD: 0.50; 95% CI: 0.14, 0.86; I2 = 00.0%) activities. However our results show that omega-3 FAs supplementation have no significant effects on HDL, LDL and blood pressure.ConclusionThis systematic review and meta-analysis supports current evidence for the clinical benefit of omega-3 FAs intake to improve cardiometabolic parameters in CKD patients. However, well-designed RCTs still needed to provide a conclusive picture in this field.

Report this publication


Seen <100 times